Lucid Diagnostics Inc (NASDAQ: LUCD)’s stock price has increased by 1.94 compared to its previous closing price of 1.55. However, the company has seen a 0.64% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-27 that Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK, March 27, 2025 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled “Embrace the Future”, designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featured at Digestive Disease Week (DDW) 2025, the world’s premier meeting for gastroenterologists and other digestive disease professionals, to be held in May.
Is It Worth Investing in Lucid Diagnostics Inc (NASDAQ: LUCD) Right Now?
The stock has a 36-month beta value of 1.27. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LUCD is 31.75M, and at present, short sellers hold a 3.83% of that float. On March 27, 2025, the average trading volume of LUCD was 633.87K shares.
LUCD’s Market Performance
The stock of Lucid Diagnostics Inc (LUCD) has seen a 0.64% increase in the past week, with a 10.88% rise in the past month, and a 103.84% gain in the past quarter. The volatility ratio for the week is 7.51%, and the volatility levels for the past 30 days are at 9.54% for LUCD. The simple moving average for the past 20 days is 11.66% for LUCD’s stock, with a 67.66% simple moving average for the past 200 days.
Analysts’ Opinion of LUCD
Many brokerage firms have already submitted their reports for LUCD stocks, with Ascendiant Capital Markets repeating the rating for LUCD by listing it as a “Buy.” The predicted price for LUCD in the upcoming period, according to Ascendiant Capital Markets is $16 based on the research report published on December 27, 2021 of the previous year 2021.
Needham, on the other hand, stated in their research note that they expect to see LUCD reach a price target of $17. The rating they have provided for LUCD stocks is “Buy” according to the report published on November 08th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to LUCD, setting the target price at $21 in the report published on November 08th of the previous year.
LUCD Trading at 26.95% from the 50-Day Moving Average
After a stumble in the market that brought LUCD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.25% of loss for the given period.
Volatility was left at 9.54%, however, over the last 30 days, the volatility rate increased by 7.51%, as shares surge +4.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +90.10% upper at present.
During the last 5 trading sessions, LUCD remain unchanged, which changed the moving average for the period of 200-days by +103.63% in comparison to the 20-day moving average, which settled at $1.4145. In addition, Lucid Diagnostics Inc saw 92.99% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for LUCD
Current profitability levels for the company are sitting at:
- -10.6 for the present operating margin
- -0.8 for the gross margin
The net margin for Lucid Diagnostics Inc stands at -10.48. The total capital return value is set at -6.4. Equity return is now at value -2956.43, with -157.04 for asset returns.
Based on Lucid Diagnostics Inc (LUCD), the company’s capital structure generated 0.8 points at debt to capital in total, while cash flow to debt ratio is standing at -2.08. The debt to equity ratio resting at 3.94. The interest coverage ratio of the stock is -1771.27.
Currently, EBITDA for the company is -46.05 billion with net debt to EBITDA at 0.02. When we switch over and look at the enterprise to sales, we see a ratio of 29.96. The receivables turnover for the company is 10.73for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.07.
Conclusion
To sum up, Lucid Diagnostics Inc (LUCD) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
